- At 12 weeks, nuchal translucency is 3.8 mm. Which diagnostic test is indicated now?
Answer: Chorionic villus sampling now
A nuchal translucency above 3.5 mm at 12 weeks indicates high aneuploidy risk, so you need a definitive diagnosis now. Chorionic villus sampling can be performed at 10-13 weeks and provides fetal karyotype. Amniocentesis is tempting but is not done until after 15 weeks; cell-free DNA is only a screening test, not diagnostic.
- Which of the following is the most appropriate next step in managing this patient?
Answer: Perform serial middle cerebral artery (MCA) peak systolic velocity Doppler ultrasounds.
When you encounter an Rh-negative mother with a positive antibody screen showing anti-D antibodies, you're dealing with Rh alloimmunization - a serious condition that can cause hemolytic disease of the fetus and newborn (HDFN). The key is understanding that once sensitization has occurred (evidenced by detectable anti-D antibodies), your focus shifts from prevention to monitoring and management.
The correct approach is C) serial MCA Doppler ultrasounds. With an anti-D titer of 1:32, this patient has significant alloimmunization that puts the fetus at risk for anemia due to hemolysis. MCA Doppler ultrasounds measure peak systolic velocity, which correlates with fetal anemia - when the fetus becomes anemic, blood flow velocity increases. This non-invasive monitoring allows you to detect fetal anemia early and time interventions appropriately.
A is incorrect because RhoGAM is preventive therapy given to unsensitized mothers. Once antibodies are present, RhoGAM is ineffective and unnecessary. B might seem logical, but determining paternal Rh status, while potentially useful information, doesn't change immediate management since antibodies are already present and the fetus is at risk regardless. D is wrong because amniocentesis for bilirubin (delta OD450) was the old standard but has been largely replaced by the safer, non-invasive MCA Doppler technique.
Remember: RhoGAM prevents sensitization, but once anti-D antibodies develop, switch to fetal surveillance mode with MCA Dopplers. This is a classic USMLE scenario testing your understanding of when prevention ends and monitoring begins.
- Which of the following is the most appropriate immediate action regarding her thyroid medication?
Answer: Increase the daily levothyroxine dose by approximately 25-30%.
When you encounter thyroid management questions during pregnancy, remember that thyroid hormone requirements increase significantly due to physiological changes including increased thyroid-binding globulin, expanded plasma volume, and fetal thyroid hormone needs.
This patient's TSH of 4.8 mIU/L is elevated above the pregnancy-specific range (0.1-2.5 mIU/L), indicating insufficient thyroid hormone replacement despite previously adequate control. During pregnancy, levothyroxine requirements typically increase by 25-50%, often beginning in the first trimester. The appropriate response is to increase her levothyroxine dose by approximately 25-30% and recheck levels in 4-6 weeks, making option D correct.
Option A is inappropriate because continuing the current dose with delayed monitoring will perpetuate maternal hypothyroidism, which can cause complications including preeclampsia, placental abruption, and impaired fetal neurodevelopment. Option B represents a fundamental error—propylthiouracil is an antithyroid medication used for hyperthyroidism, not hypothyroidism. Switching would worsen her condition dramatically. Option C reflects a dangerous misconception: levothyroxine doesn't cause fetal hyperthyroidism since it crosses the placenta minimally, and decreasing the dose would exacerbate maternal hypothyroidism.
Study tip: For USMLE Step 2, remember that pregnancy almost always requires increased levothyroxine dosing. When you see elevated TSH in pregnancy with known hypothyroidism, think "increase the dose." Conversely, be alert for antithyroid medication choices (PTU, methimazole) as distractors—these treat hyperthyroidism, not hypothyroidism.
- Assuming an uncomplicated pregnancy, what is the recommended frequency of prenatal visits for this patient from now until 28 weeks gestation?
Answer: Every 4 weeks
For a standard, uncomplicated pregnancy, the recommended schedule for prenatal visits is every 4 weeks until 28 weeks gestation, every 2 weeks from 28 to 36 weeks, and then weekly from 36 weeks until delivery. This schedule allows for routine monitoring of maternal and fetal well-being.
- In addition to a complete blood count, blood type with Rh status, and urinalysis, which of the following is an essential component of the initial prenatal laboratory screening panel?
Answer: Syphilis serology (RPR or VDRL)
Universal screening for syphilis is a standard and essential part of initial prenatal care in the United States. Early detection and treatment of maternal syphilis can prevent congenital syphilis, a devastating condition. Serum progesterone is not routinely checked. MSAFP is part of the second-trimester screen (15-20 weeks). The 1-hour glucose challenge test for gestational diabetes is typically performed at 24-28 weeks unless the patient has high-risk factors.
- A 24-year-old primigravid woman at 25 weeks' gestation has had an uncomplicated pregnancy. She asks what testing is recommended at this time to screen for gestational diabetes mellitus. Which of the following is the appropriate next step?
Answer: Administer a non-fasting 50-g oral glucose load followed by a 1-hour plasma glucose measurement
When you encounter gestational diabetes screening questions, focus on the standard timing (24-28 weeks) and the two-step approach used in most U.S. practices.
The correct approach is A) Administer a non-fasting 50-g oral glucose load followed by a 1-hour plasma glucose measurement. This is the standard initial screening test for gestational diabetes, performed between 24-28 weeks of gestation. The patient drinks a 50-gram glucose solution (no fasting required), and plasma glucose is measured one hour later. If the result is ≥140 mg/dL (or ≥130 mg/dL using a lower threshold), the patient proceeds to a confirmatory 3-hour glucose tolerance test.
B is incorrect because the 100-g 3-hour oral glucose tolerance test is the confirmatory test, not the initial screening. You only perform this second step if the 50-g screening test is abnormal.
C is wrong because hemoglobin A1c is not used for gestational diabetes screening. A1c reflects average glucose levels over 2-3 months and can be affected by the physiological changes of pregnancy, making it unreliable for this purpose.
D is incorrect because waiting until 32 weeks is too late for optimal screening. The 24-28 week window allows time for dietary management or treatment if gestational diabetes is diagnosed. Waiting for excessive fetal growth means you've missed the opportunity for early intervention.
USMLE tip: Remember the "24-28 weeks, 50g screening first" rule for gestational diabetes. The two-step approach (screen, then confirm) is standard U.S. practice and frequently tested.
- Which diagnostic procedure is most appropriate to offer this patient at her current gestational age?
Answer: Chorionic villus sampling (CVS)
For definitive genetic diagnosis in the first trimester, chorionic villus sampling (CVS) is the procedure of choice. It is typically performed between 10 and 13 weeks gestation. Amniocentesis is performed later, usually after 15 weeks gestation. PUBS is a late-trimester procedure used for specific indications like rapid karyotyping or fetal blood transfusion. Ultrasonography can identify markers suggestive of aneuploidy but is not a diagnostic genetic test.
- What is the most appropriate advice regarding exercise for this patient?
Answer: She may continue her current exercise routine, modifying as needed for comfort.
For pregnant women with no contraindications, regular exercise is encouraged. Women who were highly active before pregnancy, like this patient, can safely continue their activities, provided they stay hydrated, avoid overheating, and modify their routine as their body changes. There are no data to support discontinuing high-intensity exercise in an uncomplicated pregnancy. Strict heart rate limits are an outdated concept; perceived exertion is now the recommended guide.
- What is the most appropriate plan for GBS prophylaxis for this patient?
Answer: No intrapartum antibiotic prophylaxis is needed if she has a scheduled cesarean delivery before the onset of labor and with intact membranes.
When you encounter GBS prophylaxis questions, focus on two key factors: the delivery method and timing. GBS prophylaxis aims to prevent vertical transmission during labor and delivery, particularly when bacteria can ascend from the vagina during contractions or after membrane rupture.
The correct approach here is no intrapartum antibiotic prophylaxis (Answer A). When a cesarean delivery is performed before labor onset and with intact membranes, the risk of vertical GBS transmission is extremely low because the protective barrier remains intact and there's no prolonged exposure during labor. Current guidelines specifically state that GBS prophylaxis is not indicated in this scenario, regardless of colonization status.
Answer B is incorrect because oral antibiotics given days before delivery don't provide protection during the critical peripartum period, and GBS can rapidly recolonize after treatment ends. Answer C represents overtreatment - vancomycin would be reserved for patients with high-risk penicillin allergies (anaphylaxis, severe reactions) requiring GBS prophylaxis, but this patient doesn't need prophylaxis at all. Answer D similarly overtreats; while cefazolin could be appropriate for someone with a low-risk penicillin allergy needing GBS prophylaxis, prophylaxis isn't indicated here.
Study tip: Remember the GBS prophylaxis decision tree: First determine if prophylaxis is needed (labor status, membrane integrity), then consider antibiotic choice based on allergy severity. Scheduled cesarean with intact membranes almost always means no GBS prophylaxis needed, regardless of colonization status.
- Which of the following is the most appropriate next step in the evaluation of this finding?
Answer: Perform a detailed fetal ultrasound
An elevated MSAFP can be caused by several factors, including incorrect gestational dating, multiple gestation, fetal demise, or fetal anomalies such as neural tube defects or abdominal wall defects. The first step is to perform a detailed ultrasound to confirm the gestational age, assess for multiples, and carefully evaluate fetal anatomy. If the ultrasound is unrevealing, amniocentesis may be offered. CVS is not indicated as it is a first-trimester procedure and does not assess amniotic fluid AFP. Cell-free DNA testing screens for aneuploidy, not neural tube defects.
- 100-g OGTT (Carpenter-Coustan): fasting 96, 1-h 190, 2-h 155, 3-h 130. Diagnosis?
Answer: Gestational diabetes mellitus
Using Carpenter-Coustan criteria, GDM requires at least two of four values: fasting 95 or higher, 1-hour 180 or higher, 2-hour 155 or higher, 3-hour 140 or higher. Here fasting 96, 1-hour 190, and 2-hour 155 are all abnormal, so the diagnosis is GDM. The tempting wrong answer is impaired glucose tolerance because the 3-hour value is normal, but that doesn't matter once two thresholds are met.
- Which of the following is the most appropriate next step in counseling and management for this patient?
Answer: Offer cell-free DNA testing as a non-invasive option to further stratify her risk.
When you encounter abnormal first-trimester screening results, the key is understanding the stepwise approach to aneuploidy screening and when to escalate care. This patient has concerning results that require further risk stratification before jumping to invasive testing.
This patient's screening shows multiple red flags: nuchal translucency at the 95th percentile (normal <3.5mm but concerning when elevated), low PAPP-A (0.5 MoM, suggesting placental dysfunction), and her calculated risk of 1 in 200 is significantly higher than the typical age-related risk for a 32-year-old. These findings warrant additional testing, making cell-free DNA (cfDNA) the appropriate next step. cfDNA testing can detect fetal chromosomal abnormalities from maternal blood with >99% sensitivity for trisomy 21, providing better risk stratification without the miscarriage risk of invasive procedures.
Answer A is incorrect because these results are clearly abnormal and require follow-up. Answer B jumps too quickly to invasive testing - while CVS could provide definitive diagnosis, the standard approach is to offer additional non-invasive screening first, especially since the patient is anxious. Answer D makes no sense because repeating the same tests won't change the interpretation and delays appropriate care.
Remember that aneuploidy screening follows a stepwise approach: first-trimester combined screen → abnormal results → offer cfDNA → if cfDNA positive → offer diagnostic testing (CVS/amniocentesis). This graduated approach balances accuracy with patient autonomy while minimizing unnecessary invasive procedures. Always counsel patients that screening tests provide risk assessment, not definitive diagnosis.
- Which of the following is the most appropriate initial step in managing this finding?
Answer: Determine the paternal Kell antigen status
Anti-Kell is a clinically significant antibody that can cause severe fetal anemia. The first step in management is to assess the risk to the fetus by determining the paternal Kell antigen genotype. If the father is Kell-negative, the fetus cannot be Kell-positive, and no further surveillance is needed. If the father is Kell-positive (especially if heterozygous), the fetus is at risk, and further management with serial fetal middle cerebral artery Doppler studies would be warranted to monitor for anemia. Rho(D) immune globulin is for preventing Rh(D) alloimmunization, which is irrelevant here.
- A 27-year-old Rh-negative gravida 2 para 1 woman at 24 weeks' gestation has an anti-D antibody titer of 1:256 at her current visit (previous titer 1:32 four weeks ago). Ultrasound shows a live singleton fetus. Which of the following is the next best step in management of the pregnancy?
Answer: Schedule serial middle cerebral artery Doppler velocimetry to assess for fetal anemia
When you encounter Rh alloimmunization questions, focus on the antibody titer trends and appropriate monitoring strategies based on severity. This patient shows concerning progression: her anti-D titer has risen from 1:32 to 1:256 in just four weeks, indicating significant maternal sensitization that puts the fetus at high risk for hemolytic disease.
The correct approach is A) Schedule serial middle cerebral artery Doppler velocimetry. With titers ≥1:32 and especially with this rapid rise, you need to monitor for fetal anemia non-invasively. MCA Doppler measures peak systolic velocity, which increases when the fetus becomes anemic due to decreased blood viscosity. This allows early detection of significant fetal anemia before hydrops develops.
B) Administering RhoGAM is wrong because sensitization has already occurred - the rising titers prove her immune system is actively producing anti-D antibodies. RhoGAM prevents sensitization but cannot reverse it once established.
C) Planning cesarean at 34 weeks is premature. You need to assess fetal status first through monitoring. Delivery timing depends on the degree of fetal anemia and lung maturity, not just the titer level.
D) Immediate PUBS (percutaneous umbilical blood sampling) is too aggressive as the first step. While PUBS directly measures fetal hematocrit, it's invasive with procedural risks. MCA Doppler should be tried first; PUBS is reserved for cases where Doppler suggests severe anemia or when preparing for intrauterine transfusion.
Key strategy: In Rh alloimmunization, always escalate monitoring stepwise - start with non-invasive MCA Doppler, then proceed to invasive testing only if indicated.
- What is the most appropriate daily dose of folic acid to recommend for this patient, starting at least one month prior to attempting conception?
Answer: 4 mg
Women with a history of a prior pregnancy affected by a neural tube defect (NTD) are at high risk for recurrence. The standard recommendation for these women is high-dose folic acid supplementation of 4 mg (4000 mcg) daily, starting at least one month before conception and continuing through the first trimester. The 0.4 mg (400 mcg) dose is recommended for average-risk women.
- Cell-free DNA is negative for trisomies at 12 weeks. What additional screening is needed?
Answer: Maternal serum AFP at 16-18 wk
Cell-free DNA screens only for trisomies, not open neural tube defects. You still need maternal serum AFP at 16-18 weeks to screen for those. The tempting error is thinking no further screening is needed after a negative cfDNA result, but that would miss NTD screening.
- A 24-year-old woman at 9 weeks' gestation has no significant medical history. She reports one lifetime sexual partner but is younger than 25 years. Which additional screening test, beyond the routine prenatal panel, is specifically recommended at this visit based on her age?
Answer: Nucleic-acid amplification test for Chlamydia trachomatis (and Neisseria gonorrhoeae)
When you encounter prenatal screening questions, focus on age-specific and risk-based recommendations that go beyond standard prenatal care. The key here is recognizing that certain populations require additional screening based on epidemiological risk factors.
The correct answer is A because all sexually active women under 25 years old should be screened for chlamydia and gonorrhea using nucleic acid amplification testing (NAAT), regardless of their reported sexual history or perceived risk factors. This recommendation exists because chlamydia and gonorrhea infections are most prevalent in women under 25, often asymptomatic, and can cause serious complications during pregnancy including preterm labor, premature rupture of membranes, and neonatal infections. The patient's young age (24) makes this screening specifically indicated beyond routine prenatal testing.
Option B is incorrect because syphilis screening (RPR) is already part of the standard prenatal panel performed in the first trimester, not an additional test, and it's not limited to the third trimester. Option C is wrong because tuberculosis screening with PPD is not routinely recommended for all pregnant women—only those with specific risk factors like HIV, recent TB exposure, or high-risk populations. Option D is incorrect because gestational diabetes screening typically occurs between 24-28 weeks gestation, not at 9 weeks, and maternal age alone (24 years old) doesn't indicate early screening.
Remember this pattern: Age-based screening recommendations often target the highest-risk demographic groups. For STI screening, think "under 25" as an automatic trigger for chlamydia/gonorrhea testing, especially on obstetrics questions.
- What is the most appropriate next step in management?
Answer: Prescribe a 7-day course of oral nitrofurantoin.
This patient has asymptomatic bacteriuria, which must be treated during pregnancy to reduce the risk of complications such as pyelonephritis, preterm birth, and low birth weight. Nitrofurantoin is a safe and effective first-line antibiotic for this condition in the first and second trimesters. A test of cure should be performed after treatment. Reassurance is inappropriate as treatment is indicated. Doxycycline is a tetracycline and is contraindicated in pregnancy.
- Which of the following is the most appropriate screening test to offer this patient?
Answer: Serum quadruple screen measuring AFP, hCG, unconjugated estriol, and inhibin A.
When you encounter prenatal screening questions, timing is everything. Different screening tests are available at specific gestational windows, and you must match the appropriate test to the patient's current gestational age.
At 18 weeks gestation, this patient is in the second trimester, making the serum quadruple screen the most appropriate option. The quadruple screen (measuring AFP, hCG, unconjugated estriol, and inhibin A) is performed between 15-20 weeks and screens for trisomy 21, trisomy 18, and neural tube defects. This patient falls perfectly within this window, making choice A correct.
Choice B is incorrect because while cell-free DNA testing is highly accurate, it hasn't "superseded all other screening methods." It's typically offered in the first trimester or early second trimester (up to about 16 weeks), and this patient may be approaching the upper limit of its optimal timing.
Choice C is wrong because nuchal translucency measurement with first-trimester serum analytes is performed between 11-14 weeks. This patient is well past this window - you cannot measure nuchal translucency at 18 weeks as the fetus is too developed.
Choice D is incorrect because the patient hasn't missed the window for non-invasive screening. The quadruple screen is still available, and amniocentesis is a diagnostic test, not a screening test. While amniocentesis could be offered, screening tests should be discussed first.
Remember: First trimester screening uses nuchal translucency plus serum markers, second trimester uses the quadruple screen (15-20 weeks), and cell-free DNA bridges both but has optimal timing considerations.
- What is the most appropriate counseling to provide this patient?
Answer: Discuss the significant risks of untreated maternal depression versus the small potential fetal risks of the medication, and support continuing effective treatment.
When you encounter questions about psychiatric medications in pregnancy, you must always weigh the risks of untreated maternal mental illness against potential fetal risks from medication exposure. This risk-benefit analysis is crucial for optimal maternal and fetal outcomes.
Untreated maternal depression poses significant risks including poor prenatal care adherence, substance abuse, preterm delivery, low birth weight, and postpartum complications. These risks often outweigh the relatively small potential medication risks. For this patient who has been stable on paroxetine for two years, maintaining mental health stability is paramount.
While paroxetine (an SSRI) does carry some concerns - including a small increased risk of cardiac defects and persistent pulmonary hypertension of the newborn - these risks are relatively low and must be balanced against the substantial risks of untreated depression.
Option A is incorrect because paroxetine isn't strongly associated with major malformations, and abrupt discontinuation can cause dangerous withdrawal symptoms and depression relapse. Option B is wrong because no medication is completely safe in pregnancy - honest counseling must acknowledge potential risks. Option C is flawed because tricyclic antidepressants aren't necessarily safer than SSRIs in pregnancy and switching stable patients introduces unnecessary risks of treatment failure.
The correct approach (D) involves comprehensive counseling about both untreated depression risks and medication risks, ultimately supporting continuation of effective treatment while monitoring closely.
Remember: On Step 2, psychiatric medication questions in pregnancy almost always favor continuing effective treatment over stopping, emphasizing the serious consequences of untreated maternal mental illness.
